COMMUNIQUÉS West-GlobeNewswire

BioPorto Announces Annual Results for 2023

04/04/2024 - 08:29

April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

04/04/2024 - 07:15

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

04/04/2024 - 07:00

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “ [...]

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

04/04/2024 - 07:00

New biomarker may facilitate monitoring T1D patients’ health Increase in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG [...]

Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024

04/04/2024 - 07:00

Oslo, April 4, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with [...]

Opthea Appoints Sujal Shah to the Board of Directors

03/04/2024 - 23:39

Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE [...]

Palisade Bio Announces 1-for-15 Reverse Stock Split

03/04/2024 - 23:30

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for [...]

Attend an Upcoming True Self Awakening Retreat with Body & Brain Yoga Tai Chi

03/04/2024 - 22:53

Body & Brain Yoga Tai Chi is excited to announce an upcoming True Self Awakening Retreat scheduled for April 11-14 in Sedona, Arizona MESA, Ariz., April 03, 2024 (GLOBE NEWSWIRE) -- Body & Brain is excited to [...]

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

03/04/2024 - 22:38

- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a [...]

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

03/04/2024 - 22:30

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) SAN DIEGO, April 03, 2024 [...]

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

03/04/2024 - 22:30

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstract Company plans to provide updated interim data, including safety and [...]

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/04/2024 - 22:05

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the [...]

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03/04/2024 - 22:05

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

03/04/2024 - 22:05

Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows [...]

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03/04/2024 - 22:05

CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

03/04/2024 - 22:05

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered [...]

Nkarta to Participate in Upcoming Investor Conferences

03/04/2024 - 22:02

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two [...]

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

03/04/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has [...]

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03/04/2024 - 22:00

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]